These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
202 related articles for article (PubMed ID: 32109431)
1. Nuclear factor erythroid 2 (NF-E2)-related factor 2 (Nrf2) in autophagy-induced hepatocellular carcinoma. Zhou J; Zhang X; Tang H; Yu J; Zu X; Xie Z; Yang X; Hu J; Tan F; Li Q; Lei X Clin Chim Acta; 2020 Jul; 506():1-8. PubMed ID: 32109431 [TBL] [Abstract][Full Text] [Related]
2. Nrf2-p62 autophagy pathway and its response to oxidative stress in hepatocellular carcinoma. Bartolini D; Dallaglio K; Torquato P; Piroddi M; Galli F Transl Res; 2018 Mar; 193():54-71. PubMed ID: 29274776 [TBL] [Abstract][Full Text] [Related]
3. GSTZ1 deficiency promotes hepatocellular carcinoma proliferation via activation of the KEAP1/NRF2 pathway. Li J; Wang Q; Yang Y; Lei C; Yang F; Liang L; Chen C; Xia J; Wang K; Tang N J Exp Clin Cancer Res; 2019 Oct; 38(1):438. PubMed ID: 31666108 [TBL] [Abstract][Full Text] [Related]
4. WNK1 Interaction with KEAP1 Promotes NRF2 Stabilization to Enhance the Oxidative Stress Response in Hepatocellular Carcinoma. Li L; Xie D; Yu S; Ma M; Fan K; Chen J; Xiu M; Xie K; Li Y; Gao Y Cancer Res; 2024 Sep; 84(17):2776-2791. PubMed ID: 38885324 [TBL] [Abstract][Full Text] [Related]
5. Oxidative stress indicated by elevated expression of Nrf2 and 8-OHdG promotes hepatocellular carcinoma progression. Ma-On C; Sanpavat A; Whongsiri P; Suwannasin S; Hirankarn N; Tangkijvanich P; Boonla C Med Oncol; 2017 Apr; 34(4):57. PubMed ID: 28281193 [TBL] [Abstract][Full Text] [Related]
6. NRF2 SUMOylation promotes de novo serine synthesis and maintains HCC tumorigenesis. Guo H; Xu J; Zheng Q; He J; Zhou W; Wang K; Huang X; Fan Q; Ma J; Cheng J; Mei W; Xing R; Cai R Cancer Lett; 2019 Dec; 466():39-48. PubMed ID: 31546024 [TBL] [Abstract][Full Text] [Related]
7. Regulation and role of nuclear factor-E2-related factor 2 (Nrf2) in multidrug resistance of hepatocellular carcinoma. Tian B; Lu ZN; Guo XL Chem Biol Interact; 2018 Jan; 280():70-76. PubMed ID: 29223570 [TBL] [Abstract][Full Text] [Related]
8. Activation of AKT pathway by Nrf2/PDGFA feedback loop contributes to HCC progression. Liu D; Zhang Y; Wei Y; Liu G; Liu Y; Gao Q; Zou L; Zeng W; Zhang N Oncotarget; 2016 Oct; 7(40):65389-65402. PubMed ID: 27588483 [TBL] [Abstract][Full Text] [Related]
9. Accumulation of phosphorylated p62 is associated with NF-E2-related factor 2 activation in hepatocellular carcinoma. Shimizu T; Inoue K; Hachiya H; Shibuya N; Aoki T; Kubota K J Hepatobiliary Pancreat Sci; 2016 Aug; 23(8):467-71. PubMed ID: 27246794 [TBL] [Abstract][Full Text] [Related]
10. PKCλ/ι Loss Induces Autophagy, Oxidative Phosphorylation, and NRF2 to Promote Liver Cancer Progression. Kudo Y; Sugimoto M; Arias E; Kasashima H; Cordes T; Linares JF; Duran A; Nakanishi Y; Nakanishi N; L'Hermitte A; Campos A; Senni N; Rooslid T; Roberts LR; Cuervo AM; Metallo CM; Karin M; Diaz-Meco MT; Moscat J Cancer Cell; 2020 Aug; 38(2):247-262.e11. PubMed ID: 32589943 [TBL] [Abstract][Full Text] [Related]
11. MCUR1 facilitates epithelial-mesenchymal transition and metastasis via the mitochondrial calcium dependent ROS/Nrf2/Notch pathway in hepatocellular carcinoma. Jin M; Wang J; Ji X; Cao H; Zhu J; Chen Y; Yang J; Zhao Z; Ren T; Xing J J Exp Clin Cancer Res; 2019 Mar; 38(1):136. PubMed ID: 30909929 [TBL] [Abstract][Full Text] [Related]
12. CDCA2 protects against oxidative stress by promoting BRCA1-NRF2 signaling in hepatocellular carcinoma. Wang S; Cao K; Liao Y; Zhang W; Zheng J; Li X; Huang M; Zhong Y; Hu X; Chen D; Wang Y Oncogene; 2021 Jun; 40(25):4368-4383. PubMed ID: 34103686 [TBL] [Abstract][Full Text] [Related]
13. Phosphorylation of p62 activates the Keap1-Nrf2 pathway during selective autophagy. Ichimura Y; Waguri S; Sou YS; Kageyama S; Hasegawa J; Ishimura R; Saito T; Yang Y; Kouno T; Fukutomi T; Hoshii T; Hirao A; Takagi K; Mizushima T; Motohashi H; Lee MS; Yoshimori T; Tanaka K; Yamamoto M; Komatsu M Mol Cell; 2013 Sep; 51(5):618-31. PubMed ID: 24011591 [TBL] [Abstract][Full Text] [Related]
14. Persistent activation of Nrf2 through p62 in hepatocellular carcinoma cells. Inami Y; Waguri S; Sakamoto A; Kouno T; Nakada K; Hino O; Watanabe S; Ando J; Iwadate M; Yamamoto M; Lee MS; Tanaka K; Komatsu M J Cell Biol; 2011 Apr; 193(2):275-84. PubMed ID: 21482715 [TBL] [Abstract][Full Text] [Related]
15. Activation of tumor-promoting pathways implicated in hepatocellular adenoma/carcinoma, a long-term complication of glycogen storage disease type Ia. Cho JH; Lee YM; Bae SH; Chou JY Biochem Biophys Res Commun; 2020 Jan; 522(1):1-7. PubMed ID: 31735334 [TBL] [Abstract][Full Text] [Related]
16. NRF2 DLG Domain Mutations Identified in Japanese Liver Cancer Patients Affect the Transcriptional Activity in HCC Cell Lines. Haque E; Śmiech M; Łuczyńska K; Bouchard MF; Viger R; Kono H; Pierzchała M; Taniguchi H Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34069882 [TBL] [Abstract][Full Text] [Related]
17. Subcellular distribution and Nrf2/Keap1-interacting properties of Glutathione S-transferase P in hepatocellular carcinoma. Bartolini D; Stabile AM; Migni A; Gurrado F; Lioci G; De Franco F; Mandarano M; Svegliati-Baroni G; Di Cristina M; Bellezza G; Rende M; Galli F Arch Biochem Biophys; 2024 Jul; 757():110043. PubMed ID: 38789086 [TBL] [Abstract][Full Text] [Related]
18. Nrf2 is a potential prognostic marker and promotes proliferation and invasion in human hepatocellular carcinoma. Zhang M; Zhang C; Zhang L; Yang Q; Zhou S; Wen Q; Wang J BMC Cancer; 2015 Jul; 15():531. PubMed ID: 26194347 [TBL] [Abstract][Full Text] [Related]
19. Astragaloside IV suppresses migration and invasion of TGF-β Li L; Wang Q; He Y; Sun L; Yang Y; Pang X Naunyn Schmiedebergs Arch Pharmacol; 2022 Apr; 395(4):397-405. PubMed ID: 35092472 [TBL] [Abstract][Full Text] [Related]
20. The therapeutic effects of nicotinamide in hepatocellular carcinoma through blocking IGF-1 and effecting the balance between Nrf2 and PKB. Al-Gayyar MMH; Bagalagel A; Noor AO; Almasri DM; Diri R Biomed Pharmacother; 2019 Apr; 112():108653. PubMed ID: 30784932 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]